Key points from article :
Dr. Conlon, CEO of Nuchido, was one of the speakers at the Undoing Aging 2018.
Company has set out to translate advances in aging research into actionable therapies for humans.
Uses network impact analysis to identify combinations of interventions that impact a biological network.
Identified the decline of NAD+ as being a potential target.
NAD+ precursor supplementation alone will not deliver robust long-term benefits.
Cocktail NCD201 for 2 weeks resulted in 331% increase in NAD levels.
Data will be published upon completion of a larger in vivo study (not yet started).
Has also submitted a collaborative research proposal to screen and evaluate selective senolytic molecules.
